GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Fusen Pharmaceutical Co Ltd (HKSE:01652) » Definitions » Return-on-Tangible-Equity

Fusen Pharmaceutical Co (HKSE:01652) Return-on-Tangible-Equity : -22.69% (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Fusen Pharmaceutical Co Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Fusen Pharmaceutical Co's annualized net income for the quarter that ended in Dec. 2023 was HK$-115.4 Mil. Fusen Pharmaceutical Co's average shareholder tangible equity for the quarter that ended in Dec. 2023 was HK$508.5 Mil. Therefore, Fusen Pharmaceutical Co's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 was -22.69%.

The historical rank and industry rank for Fusen Pharmaceutical Co's Return-on-Tangible-Equity or its related term are showing as below:

HKSE:01652' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -10.24   Med: 17.93   Max: 73.12
Current: -8.18

During the past 9 years, Fusen Pharmaceutical Co's highest Return-on-Tangible-Equity was 73.12%. The lowest was -10.24%. And the median was 17.93%.

HKSE:01652's Return-on-Tangible-Equity is ranked worse than
72.81% of 934 companies
in the Drug Manufacturers industry
Industry Median: 6.265 vs HKSE:01652: -8.18

Fusen Pharmaceutical Co Return-on-Tangible-Equity Historical Data

The historical data trend for Fusen Pharmaceutical Co's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fusen Pharmaceutical Co Return-on-Tangible-Equity Chart

Fusen Pharmaceutical Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only 11.85 17.93 3.99 -7.94 -10.24

Fusen Pharmaceutical Co Semi-Annual Data
Dec15 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9.71 -2.57 -10.36 6.44 -22.69

Competitive Comparison of Fusen Pharmaceutical Co's Return-on-Tangible-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Fusen Pharmaceutical Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fusen Pharmaceutical Co's Return-on-Tangible-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Fusen Pharmaceutical Co's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Fusen Pharmaceutical Co's Return-on-Tangible-Equity falls into.



Fusen Pharmaceutical Co Return-on-Tangible-Equity Calculation

Fusen Pharmaceutical Co's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-39.679/( (437.986+336.846 )/ 2 )
=-39.679/387.416
=-10.24 %

Fusen Pharmaceutical Co's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Dec. 2023 )  (Q: Jun. 2023 )(Q: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Jun. 2023 )(Q: Dec. 2023 )
=-115.356/( (680.173+336.846)/ 2 )
=-115.356/508.5095
=-22.69 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Dec. 2023) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Fusen Pharmaceutical Co  (HKSE:01652) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Fusen Pharmaceutical Co Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Fusen Pharmaceutical Co's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Fusen Pharmaceutical Co (HKSE:01652) Business Description

Traded in Other Exchanges
N/A
Address
Urban Industrial Zone, Henan Province, Xichuan County, Zhengzhou, CHN
Fusen Pharmaceutical Co Ltd is engaged in manufacturing shuanghuanglian based cold medicine. The product portfolio company includes shuanghuanglian based cold medicine and which includes oral solutions and shuanghuanglian injections, other PCM and western medicine products which include compound ferrous sulphate granules and flunarizine hydrochloride capsules.
Executives
Cao Changcheng 2201 Interest of corporation controlled by you
Quan Xiufeng 2202 Interest of your spouse
Full Bliss Holdings Limited 2101 Beneficial owner
One Victory Investments Limited 2101 Beneficial owner
Cao Zhiming 2201 Interest of corporation controlled by you
Zhou Peilin 2202 Interest of your spouse
Rayford Global Limited 2306 Nominee for another person
Tct (bvi) Limited 2501 Other
The Core Trust Company Limited 2301 Trustee
First Joint Elegant Limited 2101 Beneficial owner
Fung Wai Sze 2202 Interest of your spouse
Lam Yiu Por 2201 Interest of corporation controlled by you

Fusen Pharmaceutical Co (HKSE:01652) Headlines

No Headlines